The primary objective of the Biostatistics/Data Management Core is to contribute to the science and operation of the Cervical SPORE by participating fully in its activities, in addition to providing assistance and direction in experimental design, data systems, quality control and statistical data analysis through consultation and collaboration;to build an infrastructure with the ability to share and manage data at Johns Hopkins University, University of Alabama at Birmingham, University of Colorado at Boulder and now Mount Sinai School of Medicine. The core will provide centralized statistical services as well as collaborative research and data management support for the research projects of the SPORE. The Core will serve as the focal point from which the SPORE investigators and career development candidates can draw statistical expertise for their research projects.
The specific aims of the Core include biostatistical consultation and support to all projects in the program, by assisting in the study design, data collection, quantitative modeling, publication, as well as interpretation, visualization and analysis of data arising in the course of program activities. The Core will also provide assistance with the identification and solution of complex database tasks arising in the course of project activities -this includes integration of clinical and basic research databases and interfaces for data entry, data retrieval, patient or sample tracking, and procedures to ensure data quality, integrity, and confidentiality at JHU and UAB. This web-based database will provide a centralized means to produce interim reports of projected progress, patient accrual, processing of specimens, completeness of data gathering, and monitoring of patient drop out or loss to follow-up. The Biostatistics/Data Management Core is led by Chenguang Wang, Ph.D., from Johns Hopkins University and Karan Singh, Ph.D., and Sejong Bae Ph.D. from University of Alabama at Birmingham. The Core is comprised of biostatisticians and supporting personnel from both JHU and UAB. All projects and other cores of the SPORE will be supported by the Biostatistics/Data Management Core.
The Biostatistics/Data Management Core aims to facilitate and manage experimental design and statistical data analysis and data management for the clinical trials conducted within the Cervical Cancer SPORE.
|Sinno, A K; Li, X; Thompson, R E et al. (2017) Trends and factors associated with radical cytoreductive surgery in the United States: A case for centralized care. Gynecol Oncol 145:493-499|
|Stewart, Katherine Ikard; Fader, Amanda N (2017) New Developments in Minimally Invasive Gynecologic Oncology Surgery. Clin Obstet Gynecol 60:330-348|
|Jiang, Rosie T; Wang, Joshua W; Peng, Shiwen et al. (2017) Spontaneous and Vaccine-Induced Clearance of Mus Musculus Papillomavirus 1 Infection. J Virol 91:|
|Yoo, Wonsuk; Kim, Sangmi; Huh, Warner K et al. (2017) Recent trends in racial and regional disparities in cervical cancer incidence and mortality in United States. PLoS One 12:e0172548|
|Moukarzel, Lea A; Angarita, Ana M; VandenBussche, Christopher et al. (2017) Preinvasive and Invasive Cervical Adenocarcinoma: Preceding Low-Risk or Negative Pap Result Increases Time to Diagnosis. J Low Genit Tract Dis 21:91-96|
|Huh, Warner K; Guido, Richard (2017) Transitioning from HPV 101 to HPV 202. Am J Obstet Gynecol 216:206-207|
|Yang, Pei-Ming; Chou, Chia-Jung; Tseng, Ssu-Hsueh et al. (2017) Bioinformatics and in vitro experimental analyses identify the selective therapeutic potential of interferon gamma and apigenin against cervical squamous cell carcinoma and adenocarcinoma. Oncotarget 8:46145-46162|
|Fader, Amanda N (2017) Minimally Invasive Techniques for Treating Gynecologic Malignancies. J Natl Compr Canc Netw 15:730-732|
|Mehta, Ambar; Xu, Tim; Hutfless, Susan et al. (2017) Patient, surgeon, and hospital disparities associated with benign hysterectomy approach and perioperative complications. Am J Obstet Gynecol 216:497.e1-497.e10|
|Yang, Andrew; Farmer, Emily; Lin, John et al. (2017) The current state of therapeutic and T cell-based vaccines against human papillomaviruses. Virus Res 231:148-165|
Showing the most recent 10 out of 273 publications